Syntara Launches $2M Share Plan at 15.6% Discount After $8M Placement

Syntara Extends Capital Raising to Retail Shareholders

Syntara Limited (ASX:SNT) is inviting its existing shareholders in Australia and New Zealand to participate in a Share Purchase Plan (SPP) aimed at raising approximately A$2 million. The offer comes hot on the heels of a recent two-tranche institutional placement that secured about A$8 million at the same issue price of A$0.027 per share, representing a 15.6% discount to the last closing price before the announcement.

The SPP allows eligible shareholders to buy up to A$30,000 worth of new fully paid ordinary shares without brokerage or transaction fees. The Board has set the offer period from 14 May to 5 June 2026, with shares expected to be issued on 11 June and commence trading the following day.

Funding Pipeline Milestones and Patent Strengthening

The net proceeds from the SPP, combined with the placement funds, are earmarked to finance five key clinical trial readouts scheduled across calendar year 2026. These milestones are critical for advancing Syntara’s pipeline, which includes amsulostat and other candidates targeting fibrotic diseases and oncology indications. The capital will also support preparatory work for the Phase 2b myelofibrosis study, including clinical trial site negotiations and formulation development.

Additionally, Syntara plans to bolster its global pan-LOX patent portfolio to maintain competitive advantage and expand potential indications. The company’s strategy to leverage intellectual property alongside clinical progress is a notable aspect of this capital raising effort.

SPP Terms and Shareholder Eligibility

Participation in the SPP is voluntary and open only to shareholders with registered addresses in Australia or New Zealand as of 28 April 2026. Notably, the offer excludes US persons and those acting on their behalf, reflecting compliance with securities laws. Applications must be made in A$1,000 increments, with a minimum of A$1,000 and a maximum of A$30,000 per shareholder. The SPP is not underwritten, and the board reserves the right to scale back applications if demand exceeds the target raise.

The issue price of A$0.027 per share is fixed for the SPP and matches the placement price, providing existing shareholders a consistent entry point. However, investors should be mindful that the market price may fluctuate between the offer and issue dates, introducing the usual risks associated with share purchase plans.

Capital Raising in the Context of Clinical Progress

This SPP follows Syntara’s successful institutional placement announced on 29 April 2026, which garnered firm commitments of approximately A$8 million to fund clinical and licensing activities. The combined capital raising aims to extend the company’s cash runway through to the third quarter of 2027, a crucial period for clinical data readouts and potential licensing deals.

Investors will recall that Syntara has been advancing multiple clinical programs, including its Phase 2b myelofibrosis trial and topical anti-fibrotic candidates, with recent regulatory progress and funding wins such as a $3 million grant for pancreatic cancer trials. These developments underscore the importance of the current capital raising to maintain momentum in a competitive biotech landscape.

Shareholders considering participation may wish to review the detailed risk disclosures in the company’s investor presentation filed with ASX on 29 April 2026, which outlines the clinical and regulatory risks inherent in Syntara’s pipeline.